Robots for this group tickers :
Swing Trader for Beginners: Trading in Markets Trending Down (TA&FA) - 30-day Annualized Return +73%
Swing Trader for Beginners: Trading in Markets Trending Up (TA&FA) - 30-day Annualized Return +33%
Urology companies, comprising EDAP (EDAP), Teleflex (TFX), and UroGen Pharma (URGN), have shown a remarkable +6.67% increase in performance over the last week. In this analysis, we delve into various indicators and metrics to better understand the current landscape and individual trajectories within this thematic sector.
Stock Outlook and Indicators
Bollinger bands and Fear & Greed Index
The Negative Outlook for these stocks is supported by the BollingerBands Indicator and the Stock Fear & Greed Index. Tickeron predicts a further decline of more than 4.00% within the next week with a likelihood of 70%. The daily ratio of advancing to declining volumes over the last week was 1 to 1.36, indicating a certain level of market indecision.
MACD Indicator
Two stocks within this thematic group have confirmed a negative outlook based on the Moving Average Convergence Divergence (MACD) indicator, with an average accuracy of 81%.
Market Capitalization Insights
The average market capitalization across the urology theme stands at 3.6 billion USD. Notably, TFX boasts the highest valuation at 10.3 billion USD, while SPHS holds the lowest valuation at 344.7 thousand USD.
Price Performance
Highs and Lows
The average weekly, weekly, and quarterly price growth across all urology stocks was 6.04%, 8.52%, and 10.75%, respectively. EDAP experienced the highest price growth at 14.42%, while TFX saw a notable fall of -0.93%. This underlines the dynamic nature of the urology theme.
Recent Declines
On 8/18/23, UroGen Pharma (URGN) experienced a significant decline of -13.11%, indicating a potential downtrend continuation. Similarly, on 1/12/23, Teleflex (TFX) recorded a decline of -6.89%.
Volume Trends
Volume Growth Metrics
The average weekly volume growth across all urology stocks was 58.89%, with weekly and quarterly averages at 45.22% and 9.77%, respectively. This suggests heightened market activity in the short term.
Record-Breaking Volumes
On 12/19/23, EDAP TMS SA saw a record-breaking daily growth of 1,669% of the 65-Day Volume Moving Average. Similar record-breaking volume growth was noted for UroGen Pharma on 12/16/23 (523%) and 4/26/23 (399%).
Individual Stock Analysis
EDAP (EDAP)
EDAP's Stochastic Oscillator is in the overbought zone for 2 days, suggesting a potential price pullback. The current price of $6.11 is below the lowest support line found by A.I. at $9.34. Despite this, the stock experienced a +19% uptrend from 12/15/23 to 01/19/24.
Teleflex (TFX)
The Momentum Indicator for TFX turned positive on January 18, 2024, indicating a potential upward trend. The odds of a move higher are at 67%. The current price of $251.41 is trading between $320.82 resistance and $248.13 support lines. TFX experienced a -3% downtrend from 12/15/23 to 01/19/24.
UroGen Pharma (URGN)
URGN's RSI Indicator recovered from the overbought zone on December 15, 2023. This signals a potential shift from an upward to a downward trend, with a 90% probability of a move down. The current price of $15.00 is trading between $17.11 support and $12.84 resistance lines. The week of 12/15/23 to 01/19/24 saw a -2% downtrend, but the week of 01/11/24 to 01/19/24 shows a +5% uptrend.
Summary
In summary, while the urology theme has seen an overall positive performance, individual stock analyses reveal nuances that investors should consider. Monitoring key indicators like the MACD, Stochastic Oscillator, and RSI can provide valuable insights into potential price movements. As always, investors should conduct thorough research and consider various factors before making investment decisions in this dynamic sector.
The 10-day RSI Oscillator for EDAP moved out of overbought territory on April 10, 2024. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 38 instances where the indicator moved out of the overbought zone. In of the 38 cases the stock moved lower in the days that followed. This puts the odds of a move down at .
The Momentum Indicator moved below the 0 level on April 15, 2024. You may want to consider selling the stock, shorting the stock, or exploring put options on EDAP as a result. In of 88 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for EDAP turned negative on April 12, 2024. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where EDAP declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
EDAP broke above its upper Bollinger Band on April 03, 2024. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 8 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
EDAP moved above its 50-day moving average on April 25, 2024 date and that indicates a change from a downward trend to an upward trend.
The 50-day moving average for EDAP moved above the 200-day moving average on April 05, 2024. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where EDAP advanced for three days, in of 257 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. EDAP’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 73, placing this stock slightly better than average.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.581) is normal, around the industry mean (14.370). EDAP's P/E Ratio (100.000) is considerably higher than the industry average of (28.511). EDAP's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (4.521). EDAP has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.032). P/S Ratio (4.303) is also within normal values, averaging (36.746).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a developer of minimally invasive medical devices for urological diseases
Industry MedicalDistributors